文献速递帕金森病与运动障碍

PD01A主动免疫治疗帕金森病的安全性与免疫原性:随机单盲1期试验

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
PubMed 文献 · Lancet Neurol · 2020-01-01

这项在奥地利维也纳开展的首次人体、随机、单盲1期试验,纳入24例早期帕金森病患者,评估针对寡聚α-突触核蛋白的主动免疫治疗PD01A(15 μg或75 μg,皮下四次基础免疫及后续加强免疫)的安全性。结果显示反复给药安全且耐受良好,可诱导显著且可被加强免疫重新激活的抗体应答,但需2期试验进一步评估疗效。

要点

  • PD01A在早期帕金森病患者中反复给药安全且耐受良好。
  • PD01A可诱导针对免疫肽的显著体液免疫应答,加强免疫后可快速重新激活。
  • 多数不良事件被认为与治疗无关,除了一过性局部注射部位反应。

核心结论

  • 反复给予PD01A在较长时间内安全且耐受良好,并诱导了具有靶点结合的大量体液免疫应答。
  • 需要2期研究进一步评估PD01A治疗帕金森病的安全性和疗效。

研究设计与样本

  • 首次人体、随机、单盲1期试验,在奥地利维也纳一家私人诊所招募45-65岁、临床诊断帕金森病≤4年且Hoehn和Yahr分期1-2期的患者。
  • 患者按1:1随机接受15 μg或75 μg PD01A皮下四次基础免疫,随访52周,随后再随访39周。
  • 患者再次按1:1随机接受15 μg或75 μg首次加强免疫,随访24周;所有患者随后接受75 μg第二次加强免疫,再随访52周。
  • 2012年2月14日至2013年2月6日共招募32例患者,24例符合条件并随机分配接受PD01A基础免疫。
  • 安全性分析纳入所有接受治疗的患者。

主要发现

  • 24例患者中21例(87%)接受了全部六次免疫并完成221-259周的在研随访。
  • 所有患者均经历至少一次不良事件,但多数被认为与研究治疗无关,除了一过性局部注射部位反应(除一例外所有患者均受影响)。
  • 系列MRI评估排除了炎症过程。
  • 系统性治疗相关不良事件包括疲劳(n=4)、头痛(n=3)、肌痛(n=3)、肌肉强直(n=2)和震颤(n=2)。
  • 抗PD01免疫肽抗体几何组平均滴度在15 μg组从基线1:46升至第12周1:3580,在75 μg组从1:76升至第12周1:2462;抗体滴度在2年内回落至基线,但在第116周起加强免疫后可快速重新激活,几何组平均滴度最高达1:20218。

临床怎么用

  • PD01A在早期帕金森病患者中显示可接受的安全性和耐受性,并诱导针对α-突触核蛋白的体液免疫应答。
  • 当前证据来自1期试验,尚不能支持临床疗效结论,需等待2期试验结果。

局限性

  • 研究为1期、单中心、样本量小(24例随机分配),主要评估安全性和免疫原性。
  • 患者对剂量分配设盲,但研究为单盲设计。
  • 缺乏疗效终点,无法评估临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robust evidence supports the role of α-synuclein pathology as a driver of neuronal dysfunction in Parkinson's disease. PD01A is a specific active immunotherapy with a short peptide formulation targeted against oligomeric α-synuclein. This phase 1 study assessed the safety and tolerability of the PD01A immunotherapeutic in patients with Parkinson's disease. METHODS: We did a first-in-human, randomised, phase 1 study of immunisations with PD01A, followed by three consecutive study extensions. Patients aged 45-65 years with a clinical diagnosis of Parkinson's disease (≤4 years since diagnosis and Hoehn and Yahr Stage 1 to 2), imaging results (dopamine transporter single photon emission CT and MRI) consistent with their Parkinson's disease diagnosis, and on stable doses of Parkinson's disease medications for at least 3 months were recruited at a single private clinic in Vienna, Austria. Patients were randomly assigned (1:1), using a computer-generated sequence with varying block size, to receive four subcutaneous immunisations with either 15 μg or 75 μg PD01A injected into the upper arms and followed up initially for 52 weeks, followed by a further 39 weeks' follow-up. Patients were then randomly assigned (1:1) again to receive the first booster immunisation at 15 μg or 75 μg and were followed up for 24 weeks. All patients received a second booster immunisation of 75 μg and were followed up for an additional 52 weeks. Patients were masked to dose allocation. Primary (safety) analyses included all treated patients. These four studies were registered with EU Clinical Trials Register, EudraCT numbers 2011-002650-31, 2013-001774-20, 2014-002489-54, and 2015-004854-16. FINDINGS: 32 patients were recruited between Feb 14, 2012, and Feb 6, 2013, and 24 were deemed eligible and randomly assigned to receive four PD01A priming immunisations. One patient had a diagnosis change to multiple system atrophy and was withdrawn and two patients withdrew consent during the studies. 21 (87%) of 24 patients received all six immunisations and completed 221-259 weeks in-study (two patients in the 15 μg dose group and one patient in the 75 μg dose group discontinued). All patients experienced at least one adverse event, but most of them were considered unrelated to study treatment (except for transient local injection site reactions, which affected all but one patient). Serial MRI assessments also ruled out inflammatory processes. Systemic treatment-related adverse events were fatigue (n=4), headache (n=3), myalgia (n=3), muscle rigidity (n=2), and tremor (n=2). The geometric group mean titre of antibodies against the immunising peptide PD01 increased from 1:46 at baseline to 1:3580 at week 12 in the 15 μg dose group, and from 1:76 to 1:2462 at week 12 in the 75 μg dose group. Antibody titres returned to baseline over 2 years, but could be rapidly reactivated after booster immunisation from week 116 onwards, reaching geometric group mean titres up to 1:20218. INTERPRETATION: Repeated administrations of PD01A were safe and well tolerated over an extended period. Specific active immunotherapy resulted in a substantial humoral immune response with target engagement. Phase 2 studies are needed to further assess the safety and efficacy of PD01A for the treatment of Parkinson's disease. FUNDING: AFFiRiS, Michael J Fox Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020. PMID: 32562684. doi:10.1016/S1474-4422(20)30136-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。